Research Article| Volume 25, ISSUE 3, P722-726, March 2016

Download started.


Predicting the Outcomes of Acute Ischemic Stroke with Rheumatic Heart Disease: The Values of CHADS2, CHA2DS2–VASc, and HAS-BLED Scores

      Background and Objective

      The CHADS2 and CHA2DS2–VASc score were used to evaluate the atrial fibrillation-related risk of stroke, and HAS-BLED score was used to estimate the oral anticoagulation-bleeding risk. We investigated the relationships between these 3 scores and the outcomes of acute ischemic stroke (AIS) patients with rheumatic heart disease (RHD) at 3 months after stroke.


      We retrospectively included patients admitted within 1 month after stroke from October 2011 to February 2014 who was also diagnosed with RHD. The patients' demographics; National Institutes of Health Stroke Scale score on admission; risk factors; prior anticoagulation; and CHADS2, CHA2DS2–VASc, and HAS-BLED scores on admission were collected, and symptomatic intracranial hemorrhage (sICH) during hospitalization was observed as well. The patients were followed up at 3 months after stroke to assess the clinical outcomes.


      Of 1425 patients with AIS, 172 patients were diagnosed with RHD. Eleven patients (6.4%) were lost to follow-up at 3 months. One hundred sixty-one patients (48 males, mean age 57.5 years) were finally analyzed in the study. The HAS-BLED score was associated with the occurrence of sICH in both univariate (P = .001; odds ratio [OR] 2.223, 95% confidence interval [CI] 1.40-3.54) and multivariate analysis (P = .031; OR 2.366, 95% CI 1.08-5.17). The CHADS2 and CHA2DS2–VASc scores were both related to the sICH (CHADS2: P = .032; OR 1.522, 95% CI 1.04-2.23; CHA2DS2–VASc: P = .011; OR 1.498, 95% CI 1.10-2.04, respectively), and to the poor outcomes at 3 months (CHADS2: P = .013; OR .688, 95% CI .51-.92; CHA2DS2–VASc: P = .014; OR .754, 95% CI .60-.94, respectively) in the univariate analysis.


      The HAS-BLED score was independently associated with the occurrence of sICH in AIS patients with RHD.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Carapetis J.R.
        • Steer A.C.
        • Mulholland E.K.
        • et al.
        The global burden of group A streptococcal diseases.
        Lancet Infect Dis. 2005; 5: 685-694
        • Zhimin W.
        • Yubao Z.
        • Lei S.
        • et al.
        Prevalence of chronic rheumatic heart disease in Chinese adults.
        Int J Cardiol. 2006; 107: 356-359
        • Wang D.
        • Liu M.
        • Hao Z.
        • et al.
        Features of acute ischemic stroke with rheumatic heart disease in a hospitalized Chinese population.
        Stroke. 2012; 43: 2853-2857
        • Camm A.J.
        • Kirchhof P.
        • Lip G.Y.
        • et al.
        Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC).
        Eur Heart J. 2010; 31: 2369-2429
        • Wann L.S.
        • Curtis A.B.
        • January C.T.
        • et al.
        2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2011; 123: 104-123
        • Furie K.L.
        • Kasner S.E.
        • Adams R.J.
        • et al.
        Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2011; 42: 227-276
        • Lip G.Y.
        • Andreotti F.
        • Fauchier L.
        • et al.
        Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis.
        Thromb Haemost. 2011; 106: 997-1011
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • et al.
        A novel user-friendly score (HAS-BLED) to assess one year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • Gage B.F.
        • Waterman A.D.
        • Shannon W.
        • et al.
        Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
        JAMA. 2001; 285: 2864-2870
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • et al.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Alonso-Coello P.
        • Bellmunt S.
        • McGorrian C.
        • et al.
        Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
        Chest. 2012; 141: e669S-e690S
        • Furie K.L.
        • Goldstein L.B.
        • Albers G.W.
        • et al.
        Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2012; 43: 3442-3453
        • Japanese Circulation Society Joint Working Group
        Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013).
        Circ J. 2014; 78: 1997-2021
        • Aho K.
        • Harmsen P.
        • Hatano S.
        • et al.
        Cerebrovascular disease in the community: results of a WHO collaborative study.
        Bull World Health Organ. 1980; 58: 113-130
        • Tan S.
        • Wang D.
        • Liu M.
        • et al.
        Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis.
        J Neurol. 2014; 261: 905-912
        • Wang D.
        • Hao Z.
        • Tao W.
        • et al.
        Acute ischemic stroke in the very elderly Chinese: risk factors, hospital management and one-year outcome.
        Clin Neurol Neurosurg. 2011; 113: 442-446
        • Brott T.
        • Adams Jr, H.P.
        • Olinger C.P.
        • et al.
        Measurements of acute cerebral infarction: a clinical examination scale.
        Stroke. 1989; 20: 864-870
        • Hacke W.
        • Kaste M.
        • Bluhmki E.
        • et al.
        Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
        N Engl J Med. 2008; 359: 1317-1329
        • de Haan R.
        • Limburg M.
        • Bossuyt P.
        • et al.
        The clinical meaning of Rankin “handicap” grades after stroke.
        Stroke. 1995; 26: 2027-2030
        • Liu M.
        Epidemiology of stroke in patients with rheumatic heart disease: A systematic review.
        Cerebrovasc Dis. 2011; 32: 26-27
        • Tanaka K.
        • Yamada T.
        • Torii T.
        • et al.
        Pre-admission CHADS(2), CHA(2)DS(2)-VASc, and R(2)CHADS(2) scores on severity and functional outcome in acute ischemic stroke with atrial fibrillation.
        J Stroke Cerebrovasc Dis. 2015; 24: 1629-1635
        • Padjen V.
        • Jovanovic D.R.
        • Leys D.
        • Beslac-Bumbasirevic L.
        Predicting the outcomes of acute ischaemic stroke in atrial fibrillation: the role of baseline CHADS2, CHA2DS2-VASC and HAS-BLED score values.
        Acta Cardiol. 2013; 68: 590-596
        • Lin S.
        • Wu B.
        • Hao Z.L.
        • et al.
        Characteristics, treatment and outcome of ischemic stroke with atrial fibrillation in a Chinese hospital-based stroke study.
        Cerebrovasc Dis. 2011; 31: 419-426
        • Camm A.J.
        • Kirchhof P.
        • Lip G.Y.H.
        • et al.
        Guidelines for the management of atrial fibrillation.
        Europace. 2010; 12: 1360-1420
        • Ogilvie I.M.
        • Newton N.
        • Welner S.A.
        • et al.
        Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
        Am J Med. 2010; 123 (e4): 638-645
        • Ottosen T.P.
        • Svendsen M.L.
        • Hansen M.L.
        • et al.
        Preadmission oral anticoagulant therapy and clinical outcome in patients hospitalised with acute stroke and atrial fibrillation.
        Dan Med J. 2014; 61: A4904
        • Sacco R.L.
        Risk factors, outcomes, and stroke subtypes for ischemic stroke.
        Neurology. 1997; 49: S39-S44
        • Sacco R.L.
        Risk factors and outcomes for ischemic stroke.
        Neurology. 1995; 45: S10-S14